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Abstract
Studies on Mycobacterium tuberculosis (MTB) antigens are of interest in order to improve vaccine efficacy and to define
biomarkers for diagnosis and treatment monitoring. The methodologies used for these investigations differ greatly between
laboratories and discordant results are common. The IFN-gamma response to two well characterized MTB antigens ESAT-6
and CFP-10, in the form of recombinant proteins and synthetic peptides, was evaluated in HIV-1 uninfected persons in both
long-term (7 day) and 24 hour, commercially available QuantiFERON TB Gold in Tube (QFT-GIT), whole blood assays. Our
findings showed differences in the IFN-gamma response between 24 hour and 7 day cultures, with recombinant proteins
inducing a significantly higher response than the peptide pools in 7 day whole blood assays. The activity of peptides and
recombinant proteins did not differ in 24 hour whole blood or peripheral blood mononuclear cell (PBMC) based assays, nor
in the ELISpot assay. Further analysis by SELDI-TOF mass spectrometry showed that the peptides are degraded over the
course of 7 days of incubation in whole blood whilst the recombinant proteins remain intact. This study therefore
demonstrates that screening antigenic candidates as synthetic peptides in long-term whole blood assays may
underestimate immunogenicity.
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Introduction
Assay of the T cell response to antigens of Mycobacterium
tuberculosis (MTB) is a research priority and critical in the
evaluation of new antigenic candidates to improve immuno-
diagnosis and vaccines. The immunogenicity of candidate antigens
is important to decide which should be selected for further studies,
and the ability to compare results is important. Various
laboratories use different techniques and readout methods to
compare the performance of new candidates. Moreover, these
potential comparisons are confounded by variations in individual
laboratory approaches that use different readout methodologies to
define the immunogenicity of such candidates [1].
The measurement of MTB antigen specific T cell Interferon
(IFN) -gamma production is used widely for determination of
immune recognition in antigen discovery. Early IFN-gamma
release assays used purified protein derivative of MTB, which has
also been used in the Tuberculin Skin Test (TST) for over one
hundred years [2,3]. Therefore these early assays had compro-
mised specificity due to cross reactivity of the immune response to
homologous proteins in tuberculous, non-tuberculous and envi-
ronmental mycobacteria. Newer IFN-gamma release assays use
MTB specific ESAT-6 and CFP-10, two co-expressed immuno-
dominant antigens encoded by the region of difference (RD)-1 of
MTB. These antigens were first evaluated in a 6-day lymphocyte
stimulation test (LST) and found to be highly specific to infer
tuberculosis infection [4,5]. IFN-gamma release assays were
subsequently developed that differed from the classical LST in
terms of cell type to be stimulated (whole blood or peripheral
blood mononuclear cells), the formulation of the antigenic
candidate (overlapping synthetic peptides or recombinant pro-
teins), duration of incubation (from ,24 hours to 7 days), or the
methods used to read out the results (proliferation, ELISA,
ELISpot, flow cytometry) [1,6–30]. Proliferation and IFN-gamma
production using PBMCs or MTB specific cell lines has been
shown to correlate irrespective of the antigenic formulation
(recombinant or synthetic overlapping peptides) of ESAT-6 and
CFP-10 [5]. IFN-gamma results from the 24 hour ELISpot assay
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(using PBMCs) and a 72 hour diluted whole blood assay (WBA)
were also found to correlate, when recombinant ESAT-6 and
CFP-10 were used [9]. Discordance between reported results have
been attributed mainly to the variation in the duration of
incubation and have been suggested to be a result of the
measurement of various components of the T cell response where
short-term assays detect circulating effector cells while long-term
assays detect the secondary effector cells that differentiate from
central memory cells during culture [28,31–34].
In the present study, we compared the commercially available
24 hour QuantiFERON TB Gold in Tube (QFT-GIT) with a
widely used 7 day WBA [1,34], as well as the ELISpot assay, using
ESAT-6 and CFP-10 to induce an IFN-gamma response. The
performance of these two antigens in the form of synthetic
overlapping peptide pools and recombinant proteins in 7 day
WBAs was also evaluated. We report differences between the
efficacy of the peptide pools and recombinant proteins to induce
IFN-gamma in the short-term, compared to the long-term assays,
using whole blood. Moreover, we used SELDI-TOF mass
spectrometry to show that the peptides are degraded over the
course of 7 days of incubation in whole blood whilst the
recombinant proteins remain intact.
Materials and Methods
Ethics Statement
The University of Cape Town Faculty of Health Sciences
Human Research Ethics Committee (REC336/2004; REC 296/
2007; REC 245/2009) approved this study. All participants
provided written informed consent.
Study Subjects
Twenty-nine healthy laboratory and clinical staff (volunteers)
with probable occupational exposure to tuberculosis were recruit-
ed. TST or HIV-1 testing was not performed. None of the
volunteers had symptoms of active TB. Ten were male, 19 female,
with median age of 27 years and 25 were BCG vaccinated.
QuantiFERON-TB Gold In Tube Assay
Commercially available QuantiFERON-TB Gold In Tube
(QFT-GIT) tests were performed as per the manufacturer’s
instructions, with the optical density values at 450 nm used to
calculate results using QuantiFERON TB Gold analysis software
v2.50 (Cellestis, Australia). A positive result is defined by
.0.35 IU/ml of IFN-c measured in the TB antigen minus nil
tube, and negative when this was ,0.35 IU/ml.
Seven Day Whole Blood Assay
A diluted whole blood assay of 7-days’ incubation was
performed as previously described [13,16,34]. Briefly, whole
blood was diluted 1:10 in RPMI 1640 medium containing 1%
(w/v) L-Glutamine. A 48 well (flat bottom) plate was set up with
the antigens and controls to a final volume of 1 ml. ESAT-6 and
CFP-10 were used as stimulants, either as peptide pools (3 mg/ml
of each peptide) or recombinant proteins (5 mg/ml). Phytohemag-
glutinin (PHA, 5 mg/ml, Sigma) was included as a positive control
and RPMI 1640 medium with 1% L-Glutamine as a negative
control. The antigens were added at 100 ml per well, followed by
900 ml of diluted blood. The plate was sealed with micro-pore tape
to avoid evaporation during incubation at 37uC with 5% CO2.
After 7 days of incubation, the supernatants were harvested and
stored at 220uC until assayed for IFN-gamma by ELISA.
IFN-gamma ELISA
Detection of IFN-gamma by ELISA was performed as
previously described [35,36] using the mouse anti-human IFN-
gamma monoclonal capture antibody (BD Pharmingen 551221)
and the biotinylated mouse anti-human IFN-gamma detection
antibody (BD Pharmingen 554550). This assay has a dynamic
range of approximately 10–3000 pg/ml. The lowest sensitivity of
Figure 1. QFT-IT results, representing the Antigen-Nil IU/ml INF-gamma values (n=29, Panel A). The solid line represents the median.
IFN-gamma response to peptide pools (covering ESAT-6, CFP-10, and Rv2654) and recombinant ESAT-6 and CFP-10 in the 7 day
WBA (n=29, Panel B). ‘‘PP’’ indicates peptide pool and ‘‘r’’ indicates the recombinant proteins. Recombinant proteins induced significantly higher
responses than the peptide pools (p,0.0001 for both ESAT-6 and CFP-10). IFN-gamma concentrations are shown as pg/ml. Lines indicate median
response.
doi:10.1371/journal.pone.0071351.g001
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the assay was 14 pg/ml and calculated values below this were
reassigned ‘zero’. Of note, 14 pg/ml IFN-gamma is equivalent to
0.35 IU/ml (www.cellestis.com). A positive response for ELISA
was defined as any response .14 pg/ml for peptide pool and
.100 pg/ml for the recombinant stimulation. Antigen specific
responses were corrected for the background response by
subtraction.
Cell Culture
Peripheral blood mononuclear cells (PBMC) were separated
over Ficoll as previously described [37]. Cells were frozen and
stored in liquid nitrogen until analyzed, when they were set up at
250000/200 ml RPMI/10% FCS (R10) per well in 96U plates in
the presence of various stimuli. Incubation periods ranged from
overnight to 3, 5, and 7 days at 37uC in 5% CO2. At the end of the
incubation period, plates were centrifuged to pellet the cells, cell
free supernatants were collected and stored at 220uC until the
ELISA was performed in batches.
IFN-gamma ELISPOT Assay
The IFN-gamma ELISpot assay was performed as previously
described [37], using mAb 1-D1K Pre-coated One-step 96-well
plates (Mabtech; 3420-2ATP-10) washed with sterile PBS and
blocked with R10 for 30 min at room temperature. PBMC at
2.56105 were added in 100 ml of R10 per well, followed by the
respective antigenic stimuli. Control stimuli included anti-CD3
mAb at 100 ng/ml final concentration and unstimulated wells.
After incubation for 16–18 h at 37uC with 5% CO2, plates were
washed with PBS, and 100 ml of secondary antibody, mAb 7-B6-1-
ALP conjugate, at 0.5 mg/ml final concentration was added. After
2 h incubation at room temperature, 100 ml substrate solution
(BCIP/NBT-plus) was added until spots emerged, when the wells
were washed with tap water and allowed to dry. Spot forming cells
(SFC) were enumerated using the immunospot counter (CTL,
Cellular Technology Ltd) and confirmed by microscope (X4).
Results are quoted as spot forming cells (SFC) per 106 PBMC. All
ELISpot responses presented are corrected for the background.
Antigens
Tuberculin Purified Protein derivative (PPD) was obtained from
Evans Vaccines (Liverpool, UK). 10,000 U/ml stocks in PBS were
stored at 280uC and used at 1000 U/ml final concentration.
Recombinant rESAT-6 and rCFP-10 were obtained from
Apronex, Czech Republic. The endotoxin content of these
proteins was 1723 IU (EU)/mg for ESAT-6 and 260 IU (EU)/
mg for CFP-10. Recombinant proteins were reconstituted in PBS/
2% BSA and were used at a final concentration of 5 mg/ml.
Overlapping peptides covering ESAT-6, CFP-10 and Rv2654
were 15-mers overlapping by 10 residues obtained from Peptide
Protein Research Ltd, Oxford, UK. The individual peptides were
solubilized in 100 ml DMSO and diluted to 10 mg/ml using PBS/
2%BSA (as stock solutions). Mixtures of 17 peptides for ESAT-6
(one peptide pool), 18 peptides for CFP-10 (one peptide pool) and
Table 1. Correlation between QFT-GIT and IFN-gamma response in the 7-day whole blood assay.
Parameter ESAT-6 peptide pool CFP-10 peptide pool
Rv2654 peptide
pool rESAT-6 rCFP-10
n* 28 28 28 28 28
Spearman r 0.45 0.15 0.29 0.33 0.59
95% Confidence interval 0.08 to 0.71 20.25 to 0.50 20.10 to 0.60 20.06 to 0.63 0.26 to 0.79
p value (two-tailed) 0.017 0.45 0.13 0.086 0.001
*1 person had QFT-GIT IFN-gamma response .10 IU/ml and was therefore excluded from this analysis.
doi:10.1371/journal.pone.0071351.t001
Figure 2. IFN-gamma response of PBMC to peptide pools and
recombinant proteins in the overnight ELISpot assay (n=29).
‘‘PP’’ indicates the peptide pools and ‘‘r’’ indicates recombinant proteins
of ESAT-6 and CFP-10. No significant difference was found between the
peptide pool and recombinant protein for either ESAT-6 or CFP-10
(Wilcoxon matched pairs test). Lines indicate median response.
doi:10.1371/journal.pone.0071351.g002
Figure 3. Peptides and recombinant protein have similar
activity in prolonged PBMC culture. PBMC of two donors were
set up with either peptide pool or recombinant ESAT-6 and cultured for
1,3,5,7 days. IFN-gamma was measured in the culture supernatant by
ELISA. Filled symbols represent peptide stimulation, open symbols
represent stimulation with recombinant protein. Donor 1 is represented
by circles, and Donor 2 by squares.
doi:10.1371/journal.pone.0071351.g003
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Figure 4. SELDI-TOF mass spectrometry analysis of whole blood supernatant stimulated with ESAT-6 and CFP-10 peptide pools. (A)
ESAT-6 peptide pool stimulated whole blood at Day 0 with expected masses from 1419 Da to 1738 Da. (B) ESAT-6 peptide pool stimulated whole
blood harvested after 7 days of incubation. (C) CFP-10 peptide pool stimulated whole blood at Day 0 with expected masses from 1415 Da to 1804 Da.
(D) CFP-10 peptide pool stimulated whole blood harvested after 7 days of incubation.
doi:10.1371/journal.pone.0071351.g004
Figure 5. Recombinant ESAT-6 protein profiles on SELDI-TOF mass spectrometry. (A) Recombinant rESAT-6 protein. (B) Recombinant
ESAT-6 stimulated whole blood at Day 0 showing a peak at the predicted molecular weight of 11.7 kDa. (C) Recombinant ESAT-6 stimulated whole
blood after 7 days of incubation showing that rESAT-6 cannot be detected, while a new peak appears at 10.8 kDa.
doi:10.1371/journal.pone.0071351.g005
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14 peptides for Rv2654 (one peptide pool) were prepared in PBS/
2% BSA and the final dilution of each peptide was 3 mg/ml in the
assays.
SELDI-TOF Mass Spectrometry
NP20 ProteinChipHarrays (BioRad) were primed with 5 ml of
HPLC grade water (Sigma). Five microliters of neat supernantant
were applied to the array surface 3 times, allowing the sample to
air dry between each application. Five microliters of recombinant
ESAT-6 or CFP-10 (1 mg/ml solution) were applied twice,
allowing the sample to air dry between each application. The
arrays were then rinsed 3 times with HPLC water and allowed to
air dry for 10 min. Saturated sinapinic acid (SPA) or a-cyano-4-
hydroxycinnamic acid (CHCA) were applied twice (260.7 ml) to
each spot on the arrays, allowing the matrix to air dry between
each application.
Time-of-flight spectra were generated using a PCS-4000 mass
spectrometer (BioRad). Spectra from the peptide pools were
obtained at a laser energy of 2000 nJ (one warming shot of
2200 nJ), a focus mass of 1500 and the matrix attenuated to 1000.
Spectra from the recombinant proteins were obtained at a laser
energy of 2500 nJ (one warming shot of 2750 nJ), a focus mass of
12,000 and the matrix attenuated to 5000. Ten shots were
obtained per position. Mass accuracy was calibrated externally
using All-in-One Peptide or Protein molecular mass standards
(BioRad). Molecular weight shirts were predicted using PAWS
software (Genomic Solutions).
1-D PAGE and Western Immunoblotting
1-D gels were performed using an Invitrogen XCell SureLock
electrophoresis system. Twenty microliters of protein supernatant
were separated on a 10% Bis-Tris gel using 2-(N-morpholino)
ethanesulfonic acid (MES) buffer at 100 V for 70–80 min and
compared against SeeBlue Plus 2 pre-stained protein standard (all
Invitrogen, Carlsbad, CA). Protein gels were transferred to
Hybond-C Extra nitrocellulose membranes (GE Healthcare,
Pittsburgh, PA) in an XCell II blot electrophoretic cell (Life
Technologies, Grand Island, NY) at 20 V for 60–90 min. Each
Figure 6. Recombinant CFP-10 protein profiles on SELDI-TOF mass spectrometry. (A) Recombinant rCFP-10 protein; (B) recombinant CFP-
10 stimulated whole blood at Day 0 showing a peak at the predicted molecular weight of 12.5 kDa; (C) recombinant CFP-10 stimulated whole blood
after 7 days of incubation showing that rCFP-10 cannot be detected, while a new peak appears at 10.8 kDa.
doi:10.1371/journal.pone.0071351.g006
Figure 7. Detection of recombinant proteins by Western blot: Supernatant of whole blood stimulated with (A) rESAT-6 and (B)
rCFP-10 at Day 0 and after 7 days of incubation, in 2 donors, showing the presence of both recombinant proteins after 7 days of
incubation, including positive (recombinant proteins alone) and negative (supernatant of unstimulated whole blood) controls.
doi:10.1371/journal.pone.0071351.g007
Performance of Peptides in Whole Blood Assays
PLOS ONE | www.plosone.org 5 August 2013 | Volume 8 | Issue 8 | e71351
membrane was blocked in PBS/3% BSA/0.1% Tween 20 for 1 hr
at RT and probed with monoclonal anti-ESAT-6 (HYB 76-8CS),
polyclonal anti-CFP-10 (K8493) antibodies (both from Statens
Serum Institute, Copenhagen, Denmark), or Calgranulin A (FL-
83,Santa Cruz Biotechnology) overnight at 4uC. Dot blots to
confirm his-tagged recombinant ESAT-6 and CFP-10 were
performed by adding 5 ml of supernatant onto Hybond-C Extra
nitrocellulose membranes (Amersham, Amersham, UK) and a his-
tagged DsbA control [38]. After blocking, the membrane was
probed with Penta Anti-His Antibody Selector Kit (Qiagen)
shaking at RT for 30 min.
Statistical Analysis
The normality of data was assessed by the D’Agostino and
Pearson omnibus test using Graphpad Prism 5.0 software (www.
graphpad.com). Parametric continuous variables were assessed by
student’s paired and unpaired t-tests, and non-parametric
variables by Wilcoxon matched pairs, Kruskal Wallis test with
Dunn’s post test correction or Mann Whitney U tests. Contin-
gency analysis was by Fisher’s exact test of probability. The kappa
statistic was used to test the agreement between two tests.
Correlation was assessed by non-parametric Spearman correlation
coefficient. Differences were considered significant when p,0.05.
Results
The T Cell Response to Peptide Pools is Significantly
Lower than the Recombinant Proteins in the 7 Day
Whole Blood Assay
We first compared the commercially available overnight
QuantiFERON TB Gold in Tube (QFT-GIT) with the widely
used 7 day diluted WBA. Of the 29 tested volunteers, 14 (48%)
were found positive by the QFT-GIT test (median IFN-gamma
0.3 IU/ml, IQR 0–1.25, Figure 1, Panel A). As the QFT-GIT
assay incorporates TB7.7, which is Rv2654 of Mycobacterium
tuberculosis, we included Rv2654c as a peptide pool in the initial 7-
day diluted WBA. Using the 7 day diluted WBA with peptide
pools as stimulants, 10/29 donors (34%) responded to at least one
peptide pool. However, when recombinant proteins were used as
stimulants, 27/29 (93%) donors responded to either recombinant
ESAT-6 or CFP-10, and this difference was significant when
compared to the peptides (p,0.0001 Wilcoxon matched pairs test,
Figure 1, Panel B). The median IFN-gamma response to all
ESAT-6, CFP-10 and Rv2654 peptide pools was 0 pg/ml, while
the median response to the recombinant ESAT-6 and CFP-10 was
1878 (IQR 471–3863) and 305 pg/ml (IQR 118–1774) respec-
tively (p,0.0001 for both comparisons). A significant correlation
was observed between the QFT-GIT (IU/ml) and the 7 day WBA
(pg/ml) response to the ESAT-6 peptide pool (r = 0.45; p= 0.017)
and the recombinant CFP-10 (r = 0.59; p = 0.001) (Table 1).
We next compared the response between peptide pools and
recombinant proteins in the overnight ELISpot assay using
PBMC. As we had no recombinant Rv2654 available, these
experiments were carried out using ESAT-6 and CFP-10 (peptides
and recombinants) only. No difference in IFN-gamma induction
was observed between peptide pools and recombinant proteins in
the overnight ELISpot assay using PBMC from the same donors
(Figure 2). Considering the low endotoxin content of these
recombinant proteins, and the clear negative responses observed
in some donors in the ELISpot assay, the possibility of
contamination in the recombinant protein to induce higher IFN-
gamma responses was ruled out. Additionally, experiments using
PBMC from two donors stimulated with either peptide pools or
the recombinant proteins for 1, 3, 5 or 7 days, showed similar
concentrations of IFN-gamma secretion (Figure 3), indicating that
peptides and recombinants have similar activity in prolonged
PBMC based cultures.
SELDI-TOF MS Analysis of Whole Blood Assay
Supernatants
Because peptides are degraded more easily by proteases present
in whole blood than recombinant proteins [39,40], we hypothe-
sized that insufficient peptide concentrations were present after 7
Figure 8. Detection of His-Tagged recombinant proteins by
Western blot: in the supernatant of whole blood stimulated
with rESAT-6 and rCFP-10 at Day 0 and after 7 days of
incubation compared to a positive control, showing that the
His-tag is detectable at both Day 0 and Day 7 of culture.
doi:10.1371/journal.pone.0071351.g008
Figure 9. Detection of Calgranulin A (S100A8) by Western blot: Supernatant of whole blood stimulated with (A) rESAT-6 and (B)
rCFP-10, was probed with Calgranulin A polycolonal antibody at Day 0 and after 7 days of incubation. The data indicates the presence
of Calgranulin A after 7 days of culture, but not on Day 0.
doi:10.1371/journal.pone.0071351.g009
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days of culture to continue stimulating T cells. In order to detect
possible peptide degradation, we compared the SELDI-TOF mass
spectrometry profiles of ESAT-6 and CFP-10 peptide pools and
recombinant proteins in the supernatants of whole blood assays
from 2 donors collected at Day 0 and after 7 days of incubation. As
shown in Figure 4, the ESAT-6 and CFP-10 peptide peaks were
present at Day 0 but not detectable after 7 days of culture,
suggesting that the peptide pools were degraded during the course
of the experiment. Protein profiling of recombinant ESAT-6 and
CFP-10 showed a clear peak for each antigen, corresponding to
the predicted molecular weight at Day 0 that was still detectable at
Day 7, although present in lower concentrations (Figures 5 and 6).
Due to the low levels of rESAT-6 and rCFP-10 that were
detectable by mass spectroscopy after 7 days of culture, we
confirmed the presence of both recombinant proteins by western
blot. The results shown in Figure 7 confirm, that both
recombinant proteins are still present after 7 days of incubation.
We also observed new peaks of lower molecular weight in both
the ESAT-6 and CFP-10 protein profiles, after 7 days of culture, in
particular a highly expressed protein at 10.8 kDa. To determine
whether protein cleavage of the 39 C-terminal His-tag would
account for the new peaks of lower molecular weight, Day 0 and
Day 7 supernatants from recombinant ESAT-6 and CFP-10
stimulated whole blood were separated on a 1-D PAGE gel and
probed with penta-anti-His antibody (Figure 8). These results
showed that the His-tag was detectable at Day 0 and after 7 days
of culture for both recombinant proteins, refuting that exopepti-
dase degradation of the C-terminus could account for the change
in mass.
The peak observed at 10.8 kDa had a high intensity and
appeared after stimulation with either rESAT-6 or rCFP-10
proteins but not with the peptide pools. A database search for
proteins previously identified at an m/z of 10.8 kDa identified
Calgranulin A (S100A8) as the potential protein. Calgranulin A is
an S-100 calcium-binding protein that is expressed in a variety of
cell types including macrophages and neutrophils during acute
inflammation. In order to determine if there was an increase in
Calgranulin A after long-term culture, rESAT-6 and rCFP-10
stimulated 7-day WBA supernatants were analysed by western
blot. As shown in Figure 9, whole blood stimulated with either
rESAT-6 or rCFP-10 contained Calgranulin A after 7 days of
culture, but not at Day 0.
Discussion
In this study we investigated the secretion of IFN-c in the
commercially available QuantiFERON TB Gold in Tube (QFT-
GIT) and long-term (7 day) whole blood assays, as well as the
ELISpot assay in response to ESAT-6 and CFP-10. The
performance of these two antigens was also compared in the form
of synthetic overlapping peptide pools and recombinant proteins
in 7 day WBA and PBMC based assays (both long term culture
and ELISpot assay). Our data indicate a reduced response to
peptide pools compared to recombinant proteins in the 7-day
WBA, which has not been reported previously. The activity of
peptide pools and recombinant proteins did not differ in PBMC
cultures.
The IFN-gamma response in a 7-day culture results from
proliferating cells. Therefore assays based on prolonged culture
would depend on the presence of adequate amounts of antigenic
stimuli (either peptide or recombinant protein) during the course
of the culture period. Peptides have greater sensitivity than
recombinant proteins to degradation by proteases present in
cultured whole blood [39,40]. Our SELDI-TOF mass spectrom-
etry data suggest that peptide degradation is most probably
responsible for the reduced response observed, as the peptides are
degraded by day 7 and not available to stimulate the proliferating
T cells.
Our data also suggest that recombinant proteins are less
abundant after 7 days of whole blood culture. However, we were
clearly able to detect both recombinant proteins after 7 days of
culture by Western blot. We did investigate the possibility that new
peaks of lower molecular weight that have appeared after 7 days,
were due to C-terminal degradation of the recombinant proteins.
As we were able to detect that the His-tag was present in both Day
0 and Day 7 samples, we conclude that reduced abundance of the
recombinant proteins is most likely due to uptake, processing and
presentation by the antigen presenting cells during the culture
period.
Interestingly, one of the lower molecular weight peaks that
appeared after 7 days of incubation was observed at 10.8 kDa. A
database search identified Calgranulin A (S100A8) as the potential
candidate, and we confirmed that this molecule is indeed
detectable after 7 days of stimulation with rESAT-6 and rCFP-
10. Calgranulins are endogenously expressed at various levels in
myeloid cells (neutrophils, macrophages, dendritic cells, mono-
cytes), secreted upon cellular activation and involved in a number
of cellular functions, including cell growth and differentiation [41].
The secreted form by neutrophils enhances CD11b expression on
human monocytes, and is a potent chemotactic for leukocytes [42].
S100A8 detected by SELDI at day 7 could be the result of the
maturation process that adherent whole blood derived monocytes
go through during the incubation period, maturing into monocyte
derived macrophages, and acting as antigen presenting cells. While
this was not the focus of the present manuscript, the significance of
calgranulin A needs to be explored in further studies.
Our results of recombinant proteins used in 7 day WBA as
stimulants are in line with other published studies using the same
assay. The majority of published studies use 7 day WBA with
recombinant proteins and 24 hrs diluted/undiluted WBA with
peptide pools. Two main recent antigen discovery papers from the
Ottenhoff group use recombinant proteins [21,43]. A study
looking at diagnosing leprosy with synthetic peptides [44] uses
synthetic 20-mer peptides overlapping by 10 amino acids in
PBMC cultured for 6 days, which is the assay system where we
showed no difference between peptide pools and recombinant
proteins. We are aware of one exception [45], which evaluates and
describes novel MTB infection phase-dependent antigens in TB
patients and household contacts. The authors included 8 peptide
pools along with other recombinant proteins in a 7 day diluted
whole blood assay similar to our assay. They describe the
recognition of the 8 peptide pools as ‘‘poor’’ in both TB patients
and household contacts.
While our data is preliminary with a number of limitations, and
further confirmatory studies are warranted, we conclude that
assessment of vaccine candidates in the form of peptides should be
tested in short term assays, while long-term whole blood based
assays should be based on recombinant protein formulations.
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